Acetylon Pharmaceuticals, a developer of drugs that inhibit HDAC enzymes to treat cancer and autoimmune diseases, has raised $12.4 million of a proposed $30 million second round of equity financing, according to an SEC filing. The Boston startup, which is developing technology based on discoveries made by researchers at the Dana-Farber Cancer Institute and Harvard University, had previously raised $9.25 million in a Series A financing. Walter Ogier, the firm’s chief executive, told me in an August 2009 interview that one of his backers was the Kraft Group, the company that owns the New England Patriots. The firm has not disclosed its other investors.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
